Robert J. Bechard

Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA

Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA.

RBC Capital Partners Ltd. is a Venture Capital firm, a subsidiary of RBC Dominion Securities, Inc. founded in 1900. RBC Capital Partners Ltd. is headquartered in Toronto, Canada with offices across the globe.

Cognetix, Inc. discovered and developed drugs. Its products were used for the treatment of epilepsy, local anesthesia, heart disease, stroke, neuromuscular back pain, multiple sclerosis, and spinal cord injury. The company was founded in 1996 by Dennis B. Farrar, Baldomero M. Olivera and J. Michael McIntosh and was headquartered in Salt Lake City, UT

Foragen Technologies Management, Inc. is a venture capital firm located in Saskatoon, Saskatchewan

Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada.

Intelgenx Corp. develops oral-controlled release pharmaceutical products. The firm offers pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. The company was founded in 2003 and is headquartered in Saint-Laurent, Canada.